313 related articles for article (PubMed ID: 29104012)
1. ANGPTL3 is part of the machinery causing dyslipidemia majorily via LPL inhibition in mastitis mice.
Xiao HB; Wang JY; Sun ZL
Exp Mol Pathol; 2017 Dec; 103(3):242-248. PubMed ID: 29104012
[TBL] [Abstract][Full Text] [Related]
2. Paeoniflorin regulates GALNT2-ANGPTL3-LPL pathway to attenuate dyslipidemia in mice.
Xiao HB; Liang L; Luo ZF; Sun ZL
Eur J Pharmacol; 2018 Oct; 836():122-128. PubMed ID: 30096295
[TBL] [Abstract][Full Text] [Related]
3. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.
Gusarova V; Alexa CA; Wang Y; Rafique A; Kim JH; Buckler D; Mintah IJ; Shihanian LM; Cohen JC; Hobbs HH; Xin Y; Valenzuela DM; Murphy AJ; Yancopoulos GD; Gromada J
J Lipid Res; 2015 Jul; 56(7):1308-17. PubMed ID: 25964512
[TBL] [Abstract][Full Text] [Related]
4. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
[TBL] [Abstract][Full Text] [Related]
5. New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.
Su X; Peng DQ
Lipids Health Dis; 2018 Jan; 17(1):12. PubMed ID: 29334984
[TBL] [Abstract][Full Text] [Related]
6. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
[TBL] [Abstract][Full Text] [Related]
7. Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia.
Shoji T; Hatsuda S; Tsuchikura S; Kimoto E; Kakiya R; Tahara H; Koyama H; Emoto M; Tabata T; Nishizawa Y
Atherosclerosis; 2009 Dec; 207(2):579-84. PubMed ID: 19540497
[TBL] [Abstract][Full Text] [Related]
8. ANGPTL3 serum concentration and rare genetic variants in Finnish population.
Tikka A; Metso J; Jauhiainen M
Scand J Clin Lab Invest; 2017 Dec; 77(8):601-609. PubMed ID: 28972399
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
10. Undaria pinnatifida soluble fiber regulates Angptl3-LPL pathway to lessen hyperlipidemia in mice.
Xiao HB; Lu XY; Zhang HB; Sun ZL; Fang J
J Physiol Biochem; 2013 Dec; 69(4):719-25. PubMed ID: 23595961
[TBL] [Abstract][Full Text] [Related]
11. ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance.
Haller JF; Mintah IJ; Shihanian LM; Stevis P; Buckler D; Alexa-Braun CA; Kleiner S; Banfi S; Cohen JC; Hobbs HH; Yancopoulos GD; Murphy AJ; Gusarova V; Gromada J
J Lipid Res; 2017 Jun; 58(6):1166-1173. PubMed ID: 28413163
[TBL] [Abstract][Full Text] [Related]
12. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL).
Lee EC; Desai U; Gololobov G; Hong S; Feng X; Yu XC; Gay J; Wilganowski N; Gao C; Du LL; Chen J; Hu Y; Zhao S; Kirkpatrick L; Schneider M; Zambrowicz BP; Landes G; Powell DR; Sonnenburg WK
J Biol Chem; 2009 May; 284(20):13735-13745. PubMed ID: 19318355
[TBL] [Abstract][Full Text] [Related]
13. ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase.
Chi X; Britt EC; Shows HW; Hjelmaas AJ; Shetty SK; Cushing EM; Li W; Dou A; Zhang R; Davies BSJ
Mol Metab; 2017 Oct; 6(10):1137-1149. PubMed ID: 29031715
[TBL] [Abstract][Full Text] [Related]
14. Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits.
Mehta N; Qamar A; Qu L; Qasim AN; Mehta NN; Reilly MP; Rader DJ
Arterioscler Thromb Vasc Biol; 2014 May; 34(5):1057-63. PubMed ID: 24626437
[TBL] [Abstract][Full Text] [Related]
15. [Association between serum lipoprotein lipase level and dyslipidemia in patients with obstructive sleep apnea syndrome].
Li J; Zhang Y; Wang J; Feng P; Chen R; Cao Y; Liu C
Zhonghua Yi Xue Za Zhi; 2014 Feb; 94(6):403-7. PubMed ID: 24754980
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of 3,4,5,6-tetrahydroxyxanthone on dyslipidemia in apolipoprotein E-deficient mice.
Xiao HB; Sun ZL; Lu XY; Li DZ; Xu JP; Hu YP
Can J Physiol Pharmacol; 2008 Dec; 86(12):815-26. PubMed ID: 19088802
[TBL] [Abstract][Full Text] [Related]
17. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism.
Köster A; Chao YB; Mosior M; Ford A; Gonzalez-DeWhitt PA; Hale JE; Li D; Qiu Y; Fraser CC; Yang DD; Heuer JG; Jaskunas SR; Eacho P
Endocrinology; 2005 Nov; 146(11):4943-50. PubMed ID: 16081640
[TBL] [Abstract][Full Text] [Related]
18. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids.
Robciuc MR; Maranghi M; Lahikainen A; Rader D; Bensadoun A; Öörni K; Metso J; Minicocci I; Ciociola E; Ceci F; Montali A; Arca M; Ehnholm C; Jauhiainen M
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1706-13. PubMed ID: 23661675
[TBL] [Abstract][Full Text] [Related]
19. Genetic Mimicry Analysis Reveals the Specific Lipases Targeted by the ANGPTL3-ANGPTL8 Complex and ANGPTL4.
Landfors F; Chorell E; Kersten S
J Lipid Res; 2023 Jan; 64(1):100313. PubMed ID: 36372100
[TBL] [Abstract][Full Text] [Related]
20. Effects of exercise training on ANGPTL3/8 and ANGPTL4/8 and their associations with cardiometabolic traits.
Hoffmann WG; Chen YQ; Schwartz CS; Barber JL; Dev PK; Reasons RJ; Miranda Maravi JS; Armstrong B; Gerszten RE; Silbernagel G; Konrad RJ; Bouchard C; Sarzynski MA
J Lipid Res; 2024 Feb; 65(2):100495. PubMed ID: 38160757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
